Current state of U.S. Food and Drug Administration regulation for cellular and gene therapy products: potential cures on the horizon - Cytotherapy
BLA 125646 Tisagenlecleucel 1 FDA Briefing Document Oncologic Drugs Advisory Committee Meeting BLA 125646 Tisagenlecleucel Novar
Clonal kinetics and single-cell transcriptional profiling of CAR-T cells in patients undergoing CD19 CAR-T immunotherapy | Nature Communications
FDA staffers like Sandoz' biosimilarity data for copy of Amgen's Enbrel | Fierce Pharma
Optimizing CAR-T Cell Manufacturing Processes during Pivotal Clinical Trials - ScienceDirect
Novartis receives first ever FDA approval for a CAR-T cell therapy
FDA Advisory Committee Recommends Approval of CAR-T Cell Therapy and Two New Biosimilars | Biosimilars Law Bulletin
Tumor response and endogenous immune reactivity after administration of HER2 CAR T cells in a child with metastatic rhabdomyosarcoma | Nature Communications
The Process of CAR-T Cell Therapy | Novartis
Management guidelines for paediatric patients receiving chimeric antigen receptor T cell therapy | Nature Reviews Clinical Oncology
BLA 125646 Tisagenlecleucel 1 FDA Briefing Document Oncologic Drugs Advisory Committee Meeting BLA 125646 Tisagenlecleucel Novar
CAR T-Cell Therapy Hits Prime Time; Challenges Remain
A New Approach to Treat Childhood Leukemia: Novartis' CAR-T Therapy | Journal of Law, Medicine & Ethics | Cambridge Core
FDA Panel Unanimously Recommends Approval for Novartis' CAR-T Therapy CTL019
Fred Hutch Statement Regarding FDA Briefing About CAR T-cell Therapy
Gene Therapy Reviews Return To US FDA Advisory Committee Schedule :: Pink Sheet
Optimizing CAR-T Cell Manufacturing Processes during Pivotal Clinical Trials - ScienceDirect
BLA 125646 Tisagenlecleucel 1 FDA Briefing Document Oncologic Drugs Advisory Committee Meeting BLA 125646 Tisagenlecleucel Novar
Novartis CEO opens door to cancer patient demanding 'fair' CAR-T pricing | Fierce Pharma
